PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 433 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On... July 29, 2021 Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function... July 3, 2023 Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... April 7, 2023 Bean there done that: Can swapping to pulses be the new... February 11, 2022 Load more HOT NEWS Cancer in My Community: Continuing to Improve Australia’s Strong Cancer Survival... We want every scientist to thrive in cancer research Coronavirus reports – Part 10: “I didn’t see my mum before... EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab
